These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31124579)

  • 21. Renal dysfunction and accuracy of N-terminal pro-B-type natriuretic peptide in predicting mortality for hospitalized patients with heart failure.
    Scrutinio D; Mastropasqua F; Guida P; Ammirati E; Ricci V; Raimondo R; Frigerio M; Lagioia R; Oliva F
    Circ J; 2014; 78(10):2439-46. PubMed ID: 25168191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
    Rezk T; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Bass P; Hawkins PN; Gillmore JD
    Kidney Int; 2017 Dec; 92(6):1476-1483. PubMed ID: 28729034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Change in the NT-proBNP/Mature BNP Molar Ratio Precedes Worsening Renal Function in Patients With Acute Heart Failure: A Novel Predictor Candidate for Cardiorenal Syndrome.
    Takahama H; Nishikimi T; Takashio S; Hayashi T; Nagai-Okatani C; Asada T; Fujiwara A; Nakagawa Y; Amano M; Hamatani Y; Okada A; Amaki M; Hasegawa T; Kanzaki H; Nishimura K; Yasuda S; Kangawa K; Anzai T; Minamino N; Izumi C
    J Am Heart Assoc; 2019 Sep; 8(17):e011468. PubMed ID: 31441355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure.
    Aimo A; Januzzi JL; Vergaro G; Ripoli A; Latini R; Masson S; Magnoli M; Anand IS; Cohn JN; Tavazzi L; Tognoni G; Gravning J; Ueland T; Nymo SH; Rocca HB; Bayes-Genis A; Lupón J; de Boer RA; Yoshihisa A; Takeishi Y; Egstrup M; Gustafsson I; Gaggin HK; Eggers KM; Huber K; Tentzeris I; Wilson Tang WH; Grodin JL; Passino C; Emdin M
    Int J Cardiol; 2019 Feb; 277():166-172. PubMed ID: 30416028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
    Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
    Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.
    Sharpley FA; Fontana M; Martinez-Naharro A; Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Whelan CJ; Hawkins PN; Wechalekar AD
    Haematologica; 2020 May; 105(5):1405-1413. PubMed ID: 31399529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis.
    Briasoulis A; Bampatsias D; Petropoulos I; Rempakos A; Patras R; Theodorakakou F; Makris N; Dimopoulos MA; Stamatelopoulos K; Kastritis E
    Eur Heart J Cardiovasc Imaging; 2024 Apr; 25(5):698-707. PubMed ID: 38142437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients -  single center experience].
    Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
    Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superior predictive value for NTproBNP compared with high sensitivity cTnT in dialysis patients: a pilot prospective observational study.
    Voroneanu L; Siriopol D; Nistor I; Apetrii M; Hogas S; Onofriescu M; Covic A
    Kidney Blood Press Res; 2014; 39(6):636-47. PubMed ID: 25571877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.
    Palladini G; Lavatelli F; Russo P; Perlini S; Perfetti V; Bosoni T; Obici L; Bradwell AR; D'Eril GM; Fogari R; Moratti R; Merlini G
    Blood; 2006 May; 107(10):3854-8. PubMed ID: 16434487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor.
    Kristen AV; Rinn J; Hegenbart U; Lindenmaier D; Merkle C; Röcken C; Hardt S; Giannitsis E; Katus HA
    Clin Res Cardiol; 2015 Mar; 104(3):250-7. PubMed ID: 25331161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.
    Lilleness B; Ruberg FL; Mussinelli R; Doros G; Sanchorawala V
    Blood; 2019 Jan; 133(3):215-223. PubMed ID: 30333122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
    Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
    Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased Prognostic Value of Query Amyloid Late Enhancement Score in Light-Chain Cardiac Amyloidosis.
    Wan K; Sun J; Han Y; Liu H; Yang D; Li W; Wang J; Cheng W; Zhang Q; Zeng Z; Chen Y
    Circ J; 2018 Feb; 82(3):739-746. PubMed ID: 29093431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of the Boston University staging system in AL amyloidosis.
    Tomlinson R; Matigian N; Mollee P
    Amyloid; 2019 Sep; 26(3):125-127. PubMed ID: 31145007
    [No Abstract]   [Full Text] [Related]  

  • 36. Independent Prognostic Utility of
    Choi YJ; Koh Y; Lee HJ; Hwang IC; Park JB; Yoon YE; Kim HL; Kim HK; Kim YJ; Cho GY; Sohn DW; Paeng JC; Lee SP
    J Nucl Med; 2022 Jul; 63(7):1064-1069. PubMed ID: 34916248
    [No Abstract]   [Full Text] [Related]  

  • 37. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.
    Palladini G; Hegenbart U; Milani P; Kimmich C; Foli A; Ho AD; Vidus Rosin M; Albertini R; Moratti R; Merlini G; Schönland S
    Blood; 2014 Oct; 124(15):2325-32. PubMed ID: 25115890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.
    Kastritis E; Gavriatopoulou M; Roussou M; Migkou M; Fotiou D; Ziogas DC; Kanellias N; Eleutherakis-Papaiakovou E; Panagiotidis I; Giannouli S; Psimenou E; Marinaki S; Apostolou T; Gakiopoulou H; Tasidou A; Papassotiriou I; Terpos E; Dimopoulos MA
    Am J Hematol; 2017 Jul; 92(7):632-639. PubMed ID: 28370245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Value of N-terminal pro-B-type natriuretic peptide on long-term outcome of patients with hypertrophic cardiomyopathy].
    Meng XB; Wang WY; Zhang K; Qi Y; An SM; Wang SY; Zheng JL; Yu QJ; Tang B; Wu R; Wang SY; Gao CY; Tang YD
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Mar; 46(3):192-197. PubMed ID: 29562423
    [No Abstract]   [Full Text] [Related]  

  • 40. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
    Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
    Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.